Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility
Self-paced
Full course description
NETEC COVID-19 Webinar Series
Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility
Release Date: 12/04/2020
Expires: 12/03/2021
The estimated time to complete this enduring material is 60 minutes.
TARGET AUDIENCE
This enduring material is intended primarily for healthcare workers and teams which may include but are not limited to, medical and nursing staff, administration, education/training leadership, and infection control leadership. Staff specializing in emergency management, communications, specialized clinical areas, laboratory, facilities management and environmental services are also welcome.
EDUCATIONAL OBJECTIVES
At the conclusion of this enduring material, the participant should be better able to:
- Identify important considerations involving Monoclonal Antibody Therapeutics available for emergency use authorization (EUAs) for mild-to-moderate COVID-19 cases
- Discuss recent criteria for the FDA approved investigational therapy for outpatient settings in determining qualifications based on risk stratification
- Summarize how to operationalize the use of Monoclonal Antibody Therapeutics when implementing this strategy within your organization as derived from case studies
FACULTY AND PLANNING COMMITTEE DISCLOSURES
The following faculty** and planning committee members have no financial relationships to disclose.
- Bryan Alexander, PharmD, BCIDP, AAHIVP**
- Sarah Anderson-Fiore, MPH, CHES
- Sonia Bell, BS
- Rebecca Duchman, MSN, MA, RN, NEA-BC**
- Heidi Keeler, PhD, RN
- Allison Klajbor, BS
- G. Marshall Lyon, III, MD, M.M.Sc, BS**
- Benjamin Mattson, MS Ed
- Jason Noble, BA, BFA
- Renee Paulin, MSN, RN, CWOCN
- Brenda Ram, CMP, CHCP
- Michelle Schwedhelm, MSN, RN, NEA-BC**
- Patricia Tennill, BSN, RN
- Sharon Vanairsdale, DNP, APRN, ACNS-BC, NP-C, CEN. FAEN, FAAN
- Sami Vasistha, MS
FINANCIAL SUPPORT
This program is funded by ASPR & CDC